



MEDLAB EXPANDS IN SIGNIFICANT AREA OF ONCOLOGY WITH NEW CLINICAL TRIAL

- Focus of trial on safety and tolerability for oncology patients undergoing chemotherapy
- Trial to be headed by Professor Stephen Clarke at the Northern Cancer Institute
- Trial to test Medlab's Multibiotic™, a patented nutraceutical already in market
- Trial is for mucositis which affects over 40 per cent of chemotherapy patients¹

Medical life science company, Medlab Clinical Limited (ASX: MDC), is commencing a safety study for oncology patients undergoing chemotherapy using its patented nutraceutical product, Multibiotic™.

Medlab was granted ethics approval in May and has now received a clinical trial number ([CTN](#)) from TGA enabling the commencement of the trial.

The phase 1 clinical trial will focus on safety and tolerability for oncology patients throughout their chemotherapy treatment in reducing intestinal inflammatory ulcerations (mucositis), which leads to the development of diarrhoea and other intestinal adverse effects.

The 12-week trial will be led by Professor Stephen Clarke at the Northern Cancer Institute in St Leonards, NSW.

According to Medlab CEO, Dr Sean Hall, preliminary investigations have shown promising results in the oncology area, with Multibiotic™ potentially complementing other Medlab oncology products like NanaBis™ and NanaBidal™.

"Since mucositis is common and debilitating, it means it is a significant market globally and we are hoping this research will help improve the general wellbeing of chemotherapy patients," Dr Hall said.

Multibiotic™ is a multi-species probiotic that helps to support the natural balance of commensal bacteria in the gastrointestinal tract. MultiBiotic™ is currently in market and used to improve symptoms of medically diagnosed Irritable Bowel Syndrome.

In other oncology work, Medlab has developed two cannabis-based medicines for oncology patients, one in pain management and the other in seizures, nausea and vomiting, with the first undergoing a clinical trial with seriously ill cancer patients at Royal North Shore Hospital in Sydney.

In the cannabis clinical trial, Medlab's NanaBis™ is being administered by Medlab's small particle medicine delivery platform, NanoCelle™.

ISSUED FOR: MEDLAB CLINICAL LTD (ASX: MDC) – www.medlab.co

FOR FURTHER INFORMATION: DR SEAN HALL, CEO, MEDLAB CLINICAL
TEL: +61 2 8203 9520, sean_hall@medlab.co

ISSUED BY: HILL + KNOWLTON STRATEGIES, MARCHA VAN DEN HEUVEL
TEL +61 2 9286 1226 OR +61 468 960 457, marcha.vandenheuvel@hkstrategies.com

ABOUT MEDLAB – www.medlab.co

Medlab Clinical is an Australian based medical life science company, developing therapeutic pathways for diagnosed chronic diseases. It is advanced in developing therapies for pain management, depression and obesity as well as earning revenue from sale of nutritional products in Australia and the United States. In pain management Medlab is developing cannabis-based medicines. The Medlab developed nano-particle medicine delivery system, Nanocelle™, is being applied to its medicines, nutritional products and off-patent drugs like statins. Medlab has a growing patent portfolio.

¹ [Luiz Evaristo Ricci, Volpato Thiago, Cruvinel Silva Thais Marchini Oliveira, Vivien Thiemy Sakai, Maria Aparecida Andrade Moreira Machado, Radiation therapy and chemotherapy-induced oral mucositis in Brazilian Journal of Otorhinolaryngology, July-August 2007, Volume 73, issue 4. Pages 562-568](#)